Estamos no ar no ! Saiba mais

Myomo

MYO

Valor de mercado US$ 47,5 mi

1,20 USD

-0,10

7,69%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

1,24

+0,04

3,33%

1 dia

-7,69%

5 dias

-17,24%

1 mês

-6,98%

3 meses

14,29%

6 meses

51,13%

No acumulado do ano

21,21%

1 ano

11,11%

5 anos

-90,02%

10 anos

-99,46%

Sobre: Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.

Funcionários: 195

Saúde Instrumentos e suprimentos médicos

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 0%

Neutro 85,7%

Negativo 14,3%

Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Mary-Katherine (“Katie”) McClure as Chief Commercial Officer effective October 12, 2026, succeeding Micah Mitchell, who will be departing following a leadership transition period. Ms. McClure brings more than 20 years of.

Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer

Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced its participation at the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026 at the Lotte Palace Hotel in New York. Myomo's President and Chief Executive Officer Paul Gudonis and Chief Financial Officer.

Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Myomo Q2 Earnings Call Highlights

Myomo NYSEAMERICAN: MYO reported second-quarter 2026 revenue growth of 21% as the wearable robotics company continued shifting its patient acquisition strategy toward recurring referral sources and expanded reimbursement relationships.

Myomo Q2 Earnings Call Highlights

Myomo, Inc. (MYO) Q2 2026 Earnings Call Transcript

Myomo, Inc. (MYO) Q2 2026 Earnings Call Transcript

Myomo, Inc. (MYO) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

Myomo, Inc. (MYO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.11 per share a year ago.

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

Myomo Reports Second Quarter 2026 Financial and Operating Results

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO)(“Myomo” or the “Company”), a wearable medical robotics platform company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and six months ended June 30, 2026. “I am pleased to report that the evolution of our go-to-market approach is driving positive results. Revenue of $11.7 million exceeded our expectations, with 53% of.

Myomo Reports Second Quarter 2026 Financial and Operating Results

Myomo to Report Second Quarter 2026 Financial Results on August 5

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the second quarter ended June 30, 2026 on Wednesday, August 5, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and an.

Myomo to Report Second Quarter 2026 Financial Results on August 5

Myomo, Inc. (MYO) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript

Myomo, Inc. (MYO) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript

Myomo, Inc. (MYO) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript

Myomo Announces Participation in iAccess Alpha Virtual Best Ideas Summer Investment Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced its participation in the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026, taking place June 23–24, 2026. President and Chief Executive Officer Paul Gudonis and Chief Financial Officer David Henry will deliver a presentati.

Myomo Announces Participation in iAccess Alpha Virtual Best Ideas Summer Investment Conference

Zacks Investment Research

Myomo (MYO) Shows Fast-paced Momentum But Is Still a Bargain Stock

Myomo (MYO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Myomo (MYO) Shows Fast-paced Momentum But Is Still a Bargain Stock

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™